Pharma News, 2025

Plasma p-tau217 can reliably detect preclinical Alzheimer disease

Pfizer gains another obesity asset with $2bn deal for YaoPharma’s GLP-1RA

Amneal stock rises after FDA approves epinephrine injection

BIOSECURE Act set for Congress vote after inclusion in annual defence bill

Lunai Bioworks Advances Parkinson’s Subtype Targets Toward Preclinical Validation

Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer

The UK and US have agreed to keep tariffs on UK pharmaceutical shipments into the US at zero.

Pseudomonas aeruginosa – one of the most common hospital germs – has sophisticated mechanisms to efficiently infect the human body and evade the immune system or antibiotics.

Researchers at Mass General Brigham have modified a herpes simplex virus (HSV-1) that stimulates the immune system to attack glioblastoma cells.

Curi Bio has secured a $10 million Series B round led by Seoul-based contract research organization DreamCIS, funding that will accelerate the expansion of the company’s integrated human-relevant pr...

Bayer has started a phase 2a trial of an antibody that it hopes could provide a targeted, potentially disease-modifying therapy for Alport syndrome, a rare, genetic disease that leads to chronic kidne...

FDA Grants Priority Review to Sonrotoclax for R/R Mantle Cell Lymphoma